Payment overview · 2025
General Payments
$1,543.14
61 reported records · 16 companies
Healthcare provider profile · identity verified
Mohammad Yousuf, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DYERSBURG, TN · NPI 1881634103
Verified facts
What the public records show
CMS Open Payments records show Mohammad Yousuf, MD received $1,543.14 in general payments during 2025 across 61 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $310.12 | 20.1% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $240.91 | 15.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.53 | 13.4% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $161.20 | 10.4% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $140.06 | 9.1% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $119.65 | 7.8% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $67.40 | 4.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.65 | 3.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.28 | 3.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $46.93 | 3.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $44.69 | 2.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.09 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.24 | 1.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.35 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.48 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.56 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,543.14 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $240.91 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $220.19 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.53 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $191.44 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $161.20 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $140.06 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $119.65 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $116.72 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.51 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $67.40 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.28 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 53 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 222 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
87 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
222 | 74 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
72 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
72 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 402 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 337 | 76 |
| Levetiracetam | Levetiracetam | 249 | 26 |
| Gabapentin | Gabapentin | 245 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 245 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 222 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 45 |
| Amoxicillin | Amoxicillin | 196 | 102 |
| Promethazine Hcl | Promethazine Hcl | 186 | 36 |
| Celecoxib | Celecoxib | 184 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 55 |
| Furosemide | Furosemide | 181 | 50 |
| Metformin Hcl | Metformin Hcl | 178 | 37 |
| Alprazolam | Alprazolam | 175 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 171 | 45 |
| Omeprazole | Omeprazole | 170 | 37 |
| Potassium Chloride | Potassium Chloride | 168 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 56 |
| Mirtazapine | Mirtazapine | 128 | 18 |
| Jardiance | Empagliflozin | 124 | 20 |
| Spironolactone | Spironolactone | 124 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 123 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 121 | 42 |
| Meloxicam | Meloxicam | 120 | 46 |
| Divalproex Sodium | Divalproex Sodium | 116 | 17 |
| Sertraline Hcl | Sertraline Hcl | 116 | 16 |
| Eliquis | Apixaban | 115 | suppressed |
| Ibuprofen | Ibuprofen | 115 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 40 |
| Baclofen | Baclofen | 108 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 24 |
| Ezetimibe | Ezetimibe | 97 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 25 |
| Clonazepam | Clonazepam | 95 | 20 |
| Doxepin Hcl | Doxepin Hcl | 92 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 15 |
| Carvedilol | Carvedilol | 90 | 21 |
| Linzess | Linaclotide | 90 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 22 |
| Losartan Potassium | Losartan Potassium | 88 | 29 |
| Ozempic | Semaglutide | 88 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 88 | 12 |
| Vraylar | Cariprazine Hcl | 87 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 19 |
| Trintellix | Vortioxetine Hydrobromide | 84 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 20 |
| Clonidine Hcl | Clonidine Hcl | 81 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | suppressed |
| Famotidine | Famotidine | 78 | 25 |
| Pregabalin | Pregabalin | 78 | 12 |
| Farxiga | Dapagliflozin Propanediol | 72 | 22 |
| Rexulti | Brexpiprazole | 72 | 24 |
| Buspirone Hcl | Buspirone Hcl | 71 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 70 | 42 |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 21 |
| Diazepam | Diazepam | 60 | 15 |
| Lisinopril | Lisinopril | 59 | 21 |
| Nabumetone | Nabumetone | 58 | 23 |
| Tramadol Hcl | Tramadol Hcl | 58 | 15 |
| Cephalexin | Cephalexin | 57 | 41 |
| Mounjaro | Tirzepatide | 57 | 11 |
| Rybelsus | Semaglutide | 57 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 16 |
| Trazodone Hcl | Trazodone Hcl | 55 | 17 |
| Creon | Lipase/Protease/Amylase | 53 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 19 |
| Entresto | Sacubitril/Valsartan | 52 | 14 |
| Donepezil Hcl | Donepezil Hcl | 49 | 15 |
| Allopurinol | Allopurinol | 48 | 14 |
| Azithromycin | Azithromycin | 48 | 36 |
| Nystatin | Nystatin | 47 | 23 |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Meclizine Hcl | Meclizine Hcl | 44 | suppressed |
| Naproxen | Naproxen | 44 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 26 |
| Methocarbamol | Methocarbamol | 40 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | 16 |
| Prednisone | Prednisone | 38 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 12 |
| Levofloxacin | Levofloxacin | 36 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 12 |
| Fluconazole | Fluconazole | 34 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 24 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 13 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 28 | 25 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Haloperidol | Haloperidol | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 16 |
| Aripiprazole | Aripiprazole | 23 | 11 |
| Cilostazol | Cilostazol | 23 | suppressed |
| Desloratadine | Desloratadine | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Acarbose | Acarbose | 22 | suppressed |
| Epinephrine | Epinephrine | 22 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Voquezna | Vonoprazan Fumarate | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,543.14 · 61 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, IBSRELA, JOURNAVX, Kerendia, OTEZLA, Ohtuvayre, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UZEDY, VYEPTI, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error